Primary and Secondary CD59 Deficiency
Publisher
Springer New York
Reference34 articles.
1. Ben-Zeev B, Tabib A, Nissenkorn A, Garti BZ, Gomori JM, Nass D, Goldshmidt H, Fellig Y, Anikster Y, Nevo Y, Elpeleg O, Mevorach D. Devastating recurrent brain ischemic infarctions and retinal disease in pediatric patients with CD59 deficiency. Eur J Paediatr Neurol. 2015;19:688–93. 2. Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, Gaya A, Coyle L, de Castro C, Fu CL, Maciejewski JP, Bessler M, Kroon HA, Rother RP, Hillmen P. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840–7. 3. Dalakas MC, Engel WK. Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch Neurol. 1980;37:637–40. 4. Grunewald M, Grunewald A, Schmid A, Schopflin C, Schauer S, Griesshammer M, Koksch M. The platelet function defect of paroxysmal nocturnal haemoglobinuria. Platelets. 2004;15:145–54. 5. Haliloglu G, Maluenda J, Sayinbatur B, Aumont C, Temucin C, Tavil B, Cetin M, Oguz KK, Gut I, Picard V, Melki J, Topaloglu H. Early-onset chronic axonal neuropathy, strokes, and hemolysis: inherited CD59 deficiency. Neurology. 2015;84:1220–4.
|
|